← GPCalc

NICE Suspected Cancer Referral

NICE NG12 Suspected cancer: recognition and referral (last updated 15 April 2026) · adults and children

Patient

Symptoms & signs

Nothing ticked yet.

Results & investigations

Pigmented skin lesion – 7-point checklist

7-point score: 0

NICE-recommended actions

Enter age and tick symptoms, signs or results to see the NICE actions.

Decision support only, based on NICE NG12 (15 April 2026). 'Unexplained' means not explained after initial assessment, including history, examination and primary care tests. Many symptoms here need clinical judgement and some (e.g. acute haematemesis, cord compression, neutropenic sepsis) need emergency care regardless. Local pathways and referral forms apply.

Quick reference

Action levels & definitions
  • Immediatean acute admission or referral within a few hours
  • Very urgent (48 h)referral or test within 48 hours
  • Refer – suspected cancer pathwayreferral so that cancer is diagnosed or ruled out within the national Faster Diagnosis Standard
  • Consider suspected cancer pathway"consider" – use clinical judgement
  • Urgent direct access testGP-requested test performed within 2 weeks
  • Primary care teststests to carry out before deciding on referral
  • Assessassess for other features, then urgent investigation, a suspected cancer pathway or non-specific symptoms pathway referral
  • Non-urgentroutine referral or test

"Unexplained" = not explained by the clinician after initial assessment, including history, examination and primary care tests. Children and young people = aged 24 and under. Make referrals within 1 working day of the decision (1.16.8).

Thresholds (FIT, CA125, PSA)
TestThresholdAction
FIT≥10 µg Hb/gSuspected cancer pathway (colorectal) (1.3.2)
CA125 age 40–49≥35 IU/mLUrgent direct access abdominal and pelvic ultrasound (1.5.9). Under 40: don't use CA125 alone – consider urgent ultrasound (1.5.6)
CA125 age 50–59≥31
CA125 age 60–69≥24
CA125 age 70–79≥25
CA125 age 80+≥31
PSA age 40–49>2.5 µg/LConsider suspected cancer pathway (prostate), taking account of preferences and comorbidities (1.6.3). Under 40 or over 79: clinical judgement
PSA age 50–59>3.5
PSA age 60–69>4.5
PSA age 70–79>6.5
Browse all recommendations by cancer site
What changed in April 2026
  • Ovarian: age-banded CA125 thresholds from 40; under 40 – ultrasound rather than CA125 alone
  • Endometrial: post-menopausal bleeding not attributable to HRT – refer at 55+, consider under 55. Unscheduled bleeding on HRT – follow British Menopause Society guidance (1.5.15)
  • Unexplained weight loss at 60+ (>5% in 6 months), unexplained appetite loss and DVT – assess, then urgent investigation, suspected cancer pathway or non-specific symptoms pathway (1.13.2–1.13.4)
  • Earlier in 2025: myeloma blood tests updated (serum free light chains); oesophageal/stomach symptoms moved to suspected cancer pathway referral rather than direct access endoscopy
Patient information & leaflet
  • Explain that most people referred don't have cancer; discuss other possible diagnoses (1.14.1–1.14.2)
  • Give information on where, when, tests, results timing, bringing someone, and who to contact (1.14.3)
  • Safety-netting: explain which symptoms to watch for and when to return; written information helps (1.14.5–1.14.6)